|
|
|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
|
PROSPER Trial Demonstrates the Relationship Between the Degree of PSA Decline and Survival Outcomes
|
|
Cora Sternberg, MD
|
| Cora Sternberg, MD joins Alicia Morgans, MD, MPH highlighting a plenary presentation from the ASCO GU 2021 symposium, an analysis of overall survival and metastasis-free survival among patients in the PROSPER trial according to the depth of PSA response. In this trial, patients with non-metastatic castration-resistant prostate cancer (nmCRPC) by CT scan and bone scan, with rising PSA, with a PSA doubling time of fewer than 10 months, were randomized 2:1 to either receive ADT and enzalutamide or ADT alone.
|
|
|
|
|
|
|
|
|
|
|
|
| Predictors of Survival, Healthcare Resource Utilization, and Healthcare Costs in Veterans with Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC) |
| Stephen J. Freedland, MD |
| In this discussion, Stephen Freedland joins Alicia Morgans to discuss a health economics study that was recently published titled, Predictors of survival, healthcare resource utilization, and healthcare costs in veterans with non-metastatic castration-resistant prostate cancer. |
|
|
|
|
|
|
|
|
|
|
|
| CONDOR: Study of 18F-DCFPyL PET/CT Imaging in Patients with Suspected Recurrence of Prostate Cancer |
A. Oliver Sartor, MD and Michael J. Morris, MD
Michael Morris, Oliver Sartor, and Alicia Morgans discuss the CONDOR study, the second of two prospective clinical trials designed in collaboration with the FDA to demonstrate the diagnostic performance of PyL in patients with biochemically recurrent prostate cancer.
|
|
|
|
|
|
|
|
|
|
|
| Delaying Disease Progression in Early Nonmetastatic CRPC Treatment |
Fred Saad, MD, FRCS
In this interview, Fred Saad reviews current and new agents showing benefit in the nonmetastatic castrate-resistant prostate cancer (nmCRPC) space. Fred makes the case for earlier treatment in nmCRPC patients and how targeting the androgen receptor is extremely effective which leads to better survival rates and longer time to progression of metastatic disease. |
|
|
|
|
|
|
|
|
|
|
| Overall Survival and Metastasis-Free Survival by Depth of PSA Decline in the Phase III PROSPER Trial of Men With nmCRPC Treated with Enzalutamide |
| Maha H. A. Hussain, MD, FACP, FASCO |
| Maha Hussain presents an analysis of overall survival and metastasis-free survival among patients in the PROSPER trial according to the depth of PSA response. In this post-hoc analysis, the authors stratified patients into four groups on the basis of the level of PSA decline at nadir: <50% (referent), 50-90%, 90% or greater with nadir ≥ 0.2 ng/mL, 90% or greater with nadir <0.2 ng/mL. The authors used unstratified Cox proportional hazards analysis models to assess overall survival and MFS between these four groups. |
|
|
|
|
|
|
|
|
|
|
| PROSPER Subgroup Analysis by Age and Region: Overall Survival and Safety in Men With Nonmetastatic Castration-Resistant Prostate Cancer Receiving Androgen Deprivation Therapy Plus Enzalutamide
|
| Ugo De Giorgi |
| Ugo De Giorgi presents a subgroup analysis of the PROSPER trial examining the effect of age and region on overall survival and safety outcomes. In this post-hoc analysis, the authors demonstrated that the overall survival benefit associated with the use of enzalutamide in nmCRPC was consistent across age groups and geographic regions. Compared to placebo, enzalutamide reduced the risk of death similarly in patients aged ≥ 70 yrs and those aged < 70 yrs. |
|
|
|
|
|
| The Impact of Concomitant Prostate Cancer Therapy on Efficacy and Safety of Relugolix vs Leuprolide in Men With Advanced Prostate Cancer: Subgroup Analysis, the Phase III HERO Study |
| Daniel J. George, MD |
| Daniel George presents a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the oral GnRH receptor antagonist relugolix versus leuprolide in men with advanced prostate cancer. |
|
|
|
|
|
| Accuracy of 68Ga-PSMA-11 for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection |
| Thomas Hope, MD |
| The results of this prospective trial evaluating the role of PSMA PET demonstrated a sensitivity of 40% and specificity of 95%. Patients with larger nodes, higher preoperative PSA, and higher Gleason score had increased sensitivities. Lastly, 87% of patients with true positive disease had a biochemical recurrence following surgery. The authors concluded that optimal management based on PSMA PET results has yet to be determined. |
|
|
|
|
|
|
|
|
|
|
|
